KR102881465B1 - Rad1901-2hcl의 다형 형태 - Google Patents

Rad1901-2hcl의 다형 형태

Info

Publication number
KR102881465B1
KR102881465B1 KR1020247030285A KR20247030285A KR102881465B1 KR 102881465 B1 KR102881465 B1 KR 102881465B1 KR 1020247030285 A KR1020247030285 A KR 1020247030285A KR 20247030285 A KR20247030285 A KR 20247030285A KR 102881465 B1 KR102881465 B1 KR 102881465B1
Authority
KR
South Korea
Prior art keywords
degrees
rad1901
2hcl
solid form
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247030285A
Other languages
English (en)
Korean (ko)
Other versions
KR20240137130A (ko
Inventor
마이클 폴 크러스키
조슈아 카일 볼저
조나단 블레이크 매켄지
프라틱 쉬스
리차드 에드워즈
알렉스 에벌린
마이클 마키
Original Assignee
래디어스 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62709319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102881465(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 래디어스 파마슈티컬스, 인코포레이티드 filed Critical 래디어스 파마슈티컬스, 인코포레이티드
Publication of KR20240137130A publication Critical patent/KR20240137130A/ko
Application granted granted Critical
Publication of KR102881465B1 publication Critical patent/KR102881465B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Conductive Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Indole Compounds (AREA)
KR1020247030285A 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태 Active KR102881465B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762442921P 2017-01-05 2017-01-05
US62/442,921 2017-01-05
PCT/US2018/012714 WO2018129419A1 (en) 2017-01-05 2018-01-05 Polymorphic forms of rad1901-2hcl
KR1020237023905A KR102707399B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023905A Division KR102707399B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태

Publications (2)

Publication Number Publication Date
KR20240137130A KR20240137130A (ko) 2024-09-19
KR102881465B1 true KR102881465B1 (ko) 2025-11-04

Family

ID=62709319

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247030285A Active KR102881465B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태
KR1020217035671A Active KR102557321B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태
KR1020237023905A Active KR102707399B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태
KR1020197022624A Active KR102322802B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217035671A Active KR102557321B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태
KR1020237023905A Active KR102707399B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태
KR1020197022624A Active KR102322802B1 (ko) 2017-01-05 2018-01-05 Rad1901-2hcl의 다형 형태

Country Status (21)

Country Link
US (5) US10385008B2 (enExample)
EP (2) EP4374925A3 (enExample)
JP (3) JP7481115B2 (enExample)
KR (4) KR102881465B1 (enExample)
CN (2) CN117417263A (enExample)
AU (3) AU2018205285C9 (enExample)
CA (1) CA3047411A1 (enExample)
DK (1) DK3565542T3 (enExample)
ES (1) ES2981967T3 (enExample)
FI (1) FI3565542T3 (enExample)
HR (1) HRP20240923T1 (enExample)
HU (1) HUE067541T2 (enExample)
IL (3) IL292245B2 (enExample)
LT (1) LT3565542T (enExample)
MX (3) MX383786B (enExample)
PL (1) PL3565542T3 (enExample)
PT (1) PT3565542T (enExample)
RS (1) RS65694B1 (enExample)
SI (1) SI3565542T1 (enExample)
SM (1) SMT202400280T1 (enExample)
WO (1) WO2018129419A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4374925A3 (en) * 2017-01-05 2025-01-15 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN112423844B (zh) * 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
PH12021551319A1 (en) * 2018-12-06 2022-05-16 Radius Pharmaceuticals Inc Methods for treating cancer resistant to cdk4/6 inhibitors
CN119390714A (zh) 2019-02-12 2025-02-07 雷迪厄斯制药公司 方法和化合物
WO2023064519A1 (en) 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
CN119343330A (zh) 2022-05-25 2025-01-21 苏州科睿思制药有限公司 艾拉司群二盐酸盐的晶型及其制备方法和用途
WO2024104268A1 (zh) * 2022-11-15 2024-05-23 苏州科睿思制药有限公司 艾拉司群二盐酸盐的共晶及其制备方法和用途
WO2024252263A1 (en) 2023-06-05 2024-12-12 Berlin-Chemie Ag Solid elacestrant dihydrochloride compositions, methods of making the same, and methods of treatment using the same
EP4574811A1 (en) 2023-12-22 2025-06-25 Sandoz Ag Crystalline forms of elacestrant dihydrochloride
WO2025158416A1 (en) 2024-01-25 2025-07-31 Assia Chemical Industries Ltd. Solid state forms of elacestrant and processes for preparation thereof
WO2025181825A2 (en) * 2024-02-26 2025-09-04 Msn Laboratories Private Limited, R&D Center Solid state forms of Elacestrant dihydrochloride and their processes for the preparation
WO2025210676A1 (en) * 2024-03-30 2025-10-09 Msn Laboratories Private Limited, R&D Center Novel crystalline forms of Elacestrant dihydrochloride and processes for their preparation
CN118652186A (zh) * 2024-05-23 2024-09-17 奥锐特药业(天津)有限公司 艾拉司群二盐酸盐的新晶型及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124617A1 (en) 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
WO2016176665A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1547758A (en) 1975-07-29 1979-06-27 Shell Int Research Herbicidal composition
US4102671A (en) 1975-07-29 1978-07-25 Shell Oil Company Control of weeds with N-substituted alanine compounds
JPH01261381A (ja) 1988-04-12 1989-10-18 Nippon Soda Co Ltd オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
UA51652C2 (uk) 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5603694A (en) 1995-10-17 1997-02-18 Brown; Joe E. Infusion coil apparatus and method for delivering fluid-based agents intravascularly
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0918774B9 (en) 1996-06-27 2002-04-10 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
DE951551T1 (de) 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2302255C (en) 1997-09-09 2011-11-08 F. Hoffmann-La Roche Ag Fracture healing using pthrp analogs
FR2770842B1 (fr) 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP1037686B1 (en) 1997-12-11 2005-08-17 Alza Corporation Device for enhancing transdermal agent flux
WO1999029364A1 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
ES2238034T3 (es) 1999-12-30 2005-08-16 Signal Pharmaceuticals Llc Compuestos y metodos para la modulacion de receptores estrogenicos.
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
AU2930501A (en) 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
NZ534348A (en) 2000-01-28 2006-06-30 Endorech Inc Selective estrogen receptor modulators in combination with estrogens
US20010044431A1 (en) 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU8206401A (en) 2000-08-03 2002-02-18 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
IL154408A0 (en) 2000-08-23 2003-09-17 Akzo Nobel Nv 10-ARYL-11-H BENZO [b] FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE
MXPA03001632A (es) 2000-08-24 2004-09-10 Univ Tennessee Res Corp Moduladores receptores de androgeno selectivos y metodos para usar los mismos.
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
RU2282468C2 (ru) 2000-10-26 2006-08-27 Алза Корпорейшн Устройство для трансдермальной доставки лекарственных средств, имеющее микровыступы с покрытием
CA2444883A1 (en) 2001-04-20 2002-10-31 Alza Corporation Microprojection array having a beneficial agent containing coating
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
JP2003107278A (ja) 2001-09-28 2003-04-09 Nippon Sheet Glass Co Ltd 光モジュール及び光モジュールの作製方法
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
US6881203B2 (en) 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
DE60223844T2 (de) 2001-12-20 2008-08-28 Alza Corp., Mountain View Mikrovorsprünge zum durchstechen der haut mit stechtiefensteuerung
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
WO2003068805A2 (en) 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
ATE345125T1 (de) 2002-02-15 2006-12-15 Endorech Inc Biphenylderivate und ihre verwendung als antiandrogene
US7138426B2 (en) 2002-04-24 2006-11-21 Merck & Co., Inc. Estrogen receptor modulators
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
EP1513547A4 (en) 2002-05-23 2009-11-04 Michael F Holick USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
MXPA05000597A (es) 2002-07-19 2005-04-28 3M Innovative Properties Co Dispositivos de microaguja y aparatos de administracion por microaguja.
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
MXPA05003797A (es) 2002-10-14 2005-06-08 Novo Nordisk As Variantes de peptido-2 tipo glucagon.
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
EP1567178A4 (en) 2002-11-01 2009-07-15 Amgen Inc MODULATORS OF RECEPTORS FOR NEUTRAL THERAPY HORMONE AND SIDE-HORSE HORMONE-RELATED PROTEINS
EP1581217A4 (en) 2002-11-01 2007-07-11 Merck & Co Inc CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS
HRP20050396A2 (en) 2002-11-07 2005-06-30 Akzo Nobel N.V. Indoles useful in the treatment of androgen-receptor related diseases
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
AU2003292625B2 (en) 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
EP1603858A2 (en) 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
EP1471286A1 (en) 2003-04-24 2004-10-27 Umbra Cuscinetti S.p.A. Ball screw
JP2007505164A (ja) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類
EP1654221A2 (en) 2003-06-10 2006-05-10 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
KR20060038407A (ko) 2003-06-30 2006-05-03 알자 코포레이션 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제
KR20060029162A (ko) 2003-06-30 2006-04-04 알자 코포레이션 피부 피어싱 미세돌출부를 코팅하는 방법
CN1816324A (zh) 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
WO2005014034A1 (en) 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
BRPI0415967A (pt) 2003-10-28 2007-01-23 Alza Corp aplicação de conjugados de polìmero de peptìdeos e proteìnas terapêuticos através de microprojeções revestidas
KR20060099523A (ko) 2003-10-31 2006-09-19 알자 코포레이션 미세 돌출부 어레이를 위한 자가 작동 어플리케이터
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
AU2004292954A1 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
US20070129409A1 (en) 2003-11-20 2007-06-07 Lain-Yen Hu Androgen receptor modulators
KR20070011252A (ko) 2003-11-21 2007-01-24 알자 코포레이션 초음파 보조 경피 백신전달방법 및 시스템
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
SG149867A1 (en) 2004-01-22 2009-02-27 Lilly Co Eli Selective estrogen receptor modulators for the treatment of vasomotor symptoms
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
JP4805909B2 (ja) 2004-03-03 2011-11-02 スミスクライン ビーチャム コーポレーション 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP4402992B2 (ja) 2004-03-18 2010-01-20 株式会社日立製作所 バックアップシステム及び方法並びにプログラム
CA2562132A1 (en) 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
EP1753749B1 (en) 2004-05-03 2014-07-30 Janssen Pharmaceutica NV Novel indole derivatives as selective androgen receptor modulators (sarms)
CA2567056A1 (en) 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
MXPA06013115A (es) 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
EP1765406A4 (en) 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
ES2366193T3 (es) 2004-09-20 2011-10-18 Janssen Pharmaceutica Nv Nuevos derivados que contienen heteroátomos tetracíclicos útiles como moduladores de receptores de hormonas esteroideas sexuales.
KR101239489B1 (ko) 2004-09-29 2013-03-06 바이엘 파마 악티엔게젤샤프트 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
EP1805147B1 (en) 2004-09-30 2014-08-13 Janssen Pharmaceutica NV Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
AU2005310238A1 (en) 2004-10-29 2006-06-08 Merck Sharp & Dohme Corp. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
JP4969451B2 (ja) 2004-11-16 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）として有用な新規な複素環誘導体
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
CN101102809B (zh) 2004-11-18 2010-05-26 3M创新有限公司 涂敷微针阵列的遮蔽方法
JP2008520331A (ja) 2004-11-18 2008-06-19 トランスファーマ メディカル リミテッド 薬剤の経皮的送達のためのマイクロチャネル形成とイオントフォレーシスの組合せ
US7585877B2 (en) 2005-01-10 2009-09-08 Acadia Pharmaceuticals, Inc. Aminophenyl derivatives as selective androgen receptor modulators
US20060188555A1 (en) 2005-01-21 2006-08-24 Micheal Cormier Therapeutic peptide formulations with improved stability
WO2006113552A2 (en) 2005-04-15 2006-10-26 Smithkline Beecham Corporation Cyanoarylamines
WO2006124447A2 (en) 2005-05-13 2006-11-23 Eli Lilly And Company Substituted n-arylpyrrolidines as selective androgen receptor modulators
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
JP5204650B2 (ja) 2005-06-24 2013-06-05 イーライ リリー アンド カンパニー アンドロゲン受容体調節物質として有用なテトラヒドロカルバゾール誘導体
US20090227571A1 (en) 2005-07-01 2009-09-10 Ligand Pharmaceuticals Incorporated Androgen Receptor Modulator Compounds and Methods
US20070021216A1 (en) 2005-07-19 2007-01-25 Sony Ericsson Mobile Communications Ab Seamless gaming method and apparatus
JP5070054B2 (ja) 2005-08-01 2012-11-07 武田薬品工業株式会社 環状アミン化合物
US20070034846A1 (en) 2005-08-09 2007-02-15 Suchin Ratanasiriwilai Fastening clip for attaching rails and posts in fence structure and attachment method of the same
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
TW200730505A (en) 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
KR100645734B1 (ko) 2005-12-14 2006-11-15 주식회사 경동나비엔 난방/온수 겸용 콘덴싱 보일러의 열교환기
ES2551305T3 (es) 2005-12-28 2015-11-17 Alza Corporation Formulaciones terapéuticas estables
EA015542B1 (ru) 2006-01-24 2011-08-30 Янссен Фармацевтика Н.В. Новые 2-замещённые бензимидазолы в качестве селективных модуляторов рецептора андрогена (sarms)
JP5373405B2 (ja) 2006-03-03 2013-12-18 オリオン コーポレーション 選択的アンドロゲン受容体モジュレーター
CA2680690A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
JP4144630B2 (ja) 2006-04-14 2008-09-03 ソニー株式会社 撮像装置
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
EA200802166A1 (ru) 2006-04-20 2009-06-30 Эмджен Инк. Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
EP2024078A2 (en) 2006-04-20 2009-02-18 Velocys, Inc. Process for treating and/or forming a non-newtonian fluid using microchannel process technology
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP1876313A2 (en) 2006-07-05 2008-01-09 Andrell Investments Pty Ltd. An extrusion for fixing cladding boards to a support structure
WO2008008433A2 (en) 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
WO2008011072A2 (en) 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
US8599144B2 (en) 2006-07-31 2013-12-03 Cypress Semiconductor Corporation Grounded button for capacitive sensor
JP4345784B2 (ja) 2006-08-21 2009-10-14 ソニー株式会社 音響収音装置及び音響収音方法
CN101528214B (zh) 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
EA015644B1 (ru) 2006-08-25 2011-10-31 Арес Трейдинг С.А. Способ лечения заболеваний хряща
WO2008042571A2 (en) 2006-09-29 2008-04-10 Smithkline Beecham Corporation Substituted indole compounds
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
SI2957278T1 (sl) 2006-10-03 2017-09-29 Radius Health, Inc. Stabilni sestavek, ki obsega PTHrP, in njegova uporaba
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
US7500575B2 (en) 2006-11-28 2009-03-10 Caper, Phillips & Associates Crane trim, list, skew and snag protection system
US20080127717A1 (en) 2006-11-30 2008-06-05 Chevron Oronite S.A. Alternative pressure viscometer device
ES2473620T3 (es) 2007-02-06 2014-07-07 Hisamitsu Pharmaceutical Co., Inc. Dispositivo de microagujas para el diagnóstico de una alergia
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
KR102016673B1 (ko) 2007-04-12 2019-08-30 가부시키가이샤 니콘 방전램프
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US7696227B2 (en) 2007-04-13 2010-04-13 Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
WO2008130587A2 (en) 2007-04-16 2008-10-30 Corium International, Inc. Solvent-cast microneedle arrays containing active
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
US20110009387A1 (en) 2007-06-12 2011-01-13 Andrea Dawn Basso-Porcaro Histone h2ax (hh2ax) biomarker for fti sensitivity
US8450481B2 (en) 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
GEP20125571B (en) 2007-08-07 2012-07-10 Takeda Pharmaceutical Pyrrolidin-2-one derivatives as androgen receptor modulators
ES2612061T3 (es) 2007-09-28 2017-05-11 The Queen's University Of Belfast Dispositivo y método de suministro
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
WO2009065126A2 (en) 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
EP2297100B1 (en) 2008-05-16 2012-10-31 Eli Lilly & Company Tetrahydrocyclopenta[b]indole androgen receptor modulators
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
EP2349200A1 (en) 2008-10-15 2011-08-03 Intarcia Therapeutics, Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
KR101668502B1 (ko) 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
EP2355887B1 (en) 2008-11-18 2017-08-02 3M Innovative Properties Company Hollow microneedle array
JP5902390B2 (ja) 2008-12-26 2016-04-13 久光製薬株式会社 マイクロニードルデバイス
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
US20110006458A1 (en) 2009-04-24 2011-01-13 Corium International, Inc. Methods for manufacturing microprojection arrays
JP5702384B2 (ja) 2009-07-31 2015-04-15 スリーエム イノベイティブ プロパティズ カンパニー 中空マイクロニードルアレイ
EP2496262A2 (en) 2009-11-02 2012-09-12 Université de Genève Stabilized protein formulations and use thereof
EP2504391B1 (en) * 2009-11-25 2018-07-25 Dow Global Technologies LLC Molded polymeric article with low haze and high clarity
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
CN101912600B (zh) 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US8987319B2 (en) 2010-02-04 2015-03-24 Radius Health, Inc. Selective androgen receptor modulators
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
EP2566501B1 (en) 2010-05-04 2019-03-13 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
EP2575845B1 (en) 2010-05-28 2017-02-15 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
AU2012223279A1 (en) 2011-03-01 2013-09-26 Sloan-Kettering Institute For Cancer Research Parathyroid hormone analogs, compositions and uses thereof
JP6033280B2 (ja) 2011-04-22 2016-11-30 ラジウス ヘルス，インコーポレイテッド ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法
WO2013082418A1 (en) 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
GB201217439D0 (en) 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP4374925A3 (en) * 2017-01-05 2025-01-15 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124617A1 (en) 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
WO2016176665A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
MX2022007801A (es) 2022-08-11
US10745343B2 (en) 2020-08-18
IL292245B2 (en) 2025-04-01
IL292245A (en) 2022-06-01
MX2019007748A (es) 2019-09-09
MX2020010555A (es) 2020-10-22
SMT202400280T1 (it) 2024-09-16
SI3565542T1 (sl) 2024-08-30
AU2018205285C9 (en) 2024-05-23
AU2023202085A1 (en) 2023-05-04
US10385008B2 (en) 2019-08-20
IL292245B1 (en) 2024-12-01
AU2025205244A1 (en) 2025-07-31
DK3565542T3 (da) 2024-07-01
JP2025109740A (ja) 2025-07-25
IL267772B (en) 2022-06-01
KR20190105030A (ko) 2019-09-11
AU2023202085B2 (en) 2025-04-10
IL267772A (en) 2019-09-26
US12398094B2 (en) 2025-08-26
US20220048848A1 (en) 2022-02-17
RS65694B1 (sr) 2024-07-31
KR20210134837A (ko) 2021-11-10
US20180186726A1 (en) 2018-07-05
EP4374925A3 (en) 2025-01-15
US20200361853A1 (en) 2020-11-19
KR102707399B1 (ko) 2024-09-13
EP4374925A2 (en) 2024-05-29
KR102322802B1 (ko) 2021-11-04
MX383786B (es) 2025-03-14
US20200062694A1 (en) 2020-02-27
PT3565542T (pt) 2024-06-28
ES2981967T3 (es) 2024-10-14
FI3565542T3 (fi) 2024-06-24
HUE067541T2 (hu) 2024-10-28
AU2018205285A1 (en) 2019-07-04
US11708318B2 (en) 2023-07-25
JP7481115B2 (ja) 2024-05-10
CN110191707A (zh) 2019-08-30
KR102557321B1 (ko) 2023-07-18
US20230373904A1 (en) 2023-11-23
KR20230109795A (ko) 2023-07-20
JP2022140559A (ja) 2022-09-26
PL3565542T3 (pl) 2024-07-29
JP2020514291A (ja) 2020-05-21
HRP20240923T1 (hr) 2024-10-11
CA3047411A1 (en) 2018-07-12
AU2018205285B2 (en) 2023-04-20
LT3565542T (lt) 2024-07-10
AU2018205285C1 (en) 2023-08-24
EP3565542A1 (en) 2019-11-13
IL316617A (en) 2024-12-01
US11148996B2 (en) 2021-10-19
EP3565542A4 (en) 2020-09-02
CN117417263A (zh) 2024-01-19
EP3565542B1 (en) 2024-04-10
KR20240137130A (ko) 2024-09-19
WO2018129419A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
KR102881465B1 (ko) Rad1901-2hcl의 다형 형태
KR102792490B1 (ko) Rad1901-2hcl의 다형 형태
HK40017692A (en) Polymorphic forms of rad1901-2hcl
HK40017692B (en) Polymorphic forms of rad1901-2hcl

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601